{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:36:22Z","timestamp":1772325382945,"version":"3.50.1"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.msard.2024.105795","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T17:04:31Z","timestamp":1722445471000},"page":"105795","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Siponimod following Alemtuzumab in secondary progressive MS: investigating sequential therapy\u2013A case series"],"prefix":"10.1016","volume":"90","author":[{"given":"Aurora","family":"Zangh\u00ec","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola Sofia","family":"Di Filippo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Avolio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7494-9057","authenticated-orcid":false,"given":"Emanuele","family":"D'Amico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2024.105795_bib11","article-title":"Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World","author":"Barclay","year":"2019","journal-title":"Clinical Settings"},{"key":"10.1016\/j.msard.2024.105795_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102717","article-title":"Alemtuzumab outcomes by age: post hoc analysis from the randomized CARE-MS studies over 8 years","volume":"49","author":"Bass","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2024.105795_bib14","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.neurol.2022.09.006","article-title":"Paradigm shifts in multiple sclerosis management: Implications for daily clinical practice","volume":"179","author":"Bourre","year":"2023","journal-title":"Rev Neurol (Paris)"},{"issue":"10","key":"10.1016\/j.msard.2024.105795_bib0002","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1080\/14740338.2019.1658741","article-title":"An update on the safety of treating relapsing-remitting multiple sclerosis","volume":"18","author":"Chisari","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.msard.2024.105795_bib0003","doi-asserted-by":"crossref","unstructured":"Coyle P.K., Freedman M.S., Cohen B.A., Cree B.A.C., Markowitz C.E. Sphingosine 1-phosphate receptor modulators in multiple sclerosis treatment: a practical review. 2024;11(4):842\u201355.","DOI":"10.1002\/acn3.52017"},{"issue":"10","key":"10.1016\/j.msard.2024.105795_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17101725","article-title":"A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives","volume":"17","author":"D\u2019Amico","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.msard.2024.105795_bib0006","unstructured":"EMA\/Lemtrada, https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lemtrada. Accessed 15 May, 2024."},{"issue":"4","key":"10.1016\/j.msard.2024.105795_bib0005","article-title":"Proportion of Alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years","volume":"6","author":"Hor\u00e1kov\u00e1","year":"2020","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"3","key":"10.1016\/j.msard.2024.105795_bib0007","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/cei.13208","article-title":"Clinical pharmacology of Alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis","volume":"194","author":"Li","year":"2018","journal-title":"Clin. Exp. Immunol."},{"issue":"Pt 9","key":"10.1016\/j.msard.2024.105795_bib0008","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1093\/brain\/aww173","article-title":"Defining secondary progressive multiple sclerosis","volume":"139","author":"Lorscheider","year":"2016","journal-title":"Brain"},{"key":"10.1016\/j.msard.2024.105795_bib0004","unstructured":"Mayzent\/EMA, https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mayzent. Accessed 15 May, 2024."},{"issue":"8","key":"10.1016\/j.msard.2024.105795_bib0009","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.msard.2024.105795_bib0010","doi-asserted-by":"crossref","DOI":"10.1177\/2040622320983121","article-title":"Exploring polypharmacy phenomenon in newly diagnosed relapsing-remitting multiple sclerosis: a cohort ambispective single-centre study","volume":"12","author":"Zangh\u00ec","year":"2021","journal-title":"Ther. Adv. Chronic Dis."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824003729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824003729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T07:53:34Z","timestamp":1726386814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824003729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":13,"alternative-id":["S2211034824003729"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.105795","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Siponimod following Alemtuzumab in secondary progressive MS: investigating sequential therapy\u2013A case series","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.105795","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105795"}}